AstraZeneca is buying Fusion Pharmaceuticals for $2.4 billion as the London-listed group looks to build its presence in cutting-edge cancer treatments.
AstraZeneca to buy Fusion Pharmaceuticals for up to $2.4 billion
Read Next
- GM reveals Corvette EV concept car as it reconfirms Europe commitment
- Elon Musk brother Kimbal says Trump tariffs permanent tax on consumers
- If you often use these 7 phrases, people see you as confident and trustworthy
- Auto sales are on a ‘roller coaster ride’ as tariffs take effect
- DB Investing hires AUS Global exec Gad Elkareem to head BizDev
- Recession fears hit Starbucks, Chipotle, McDonald’s stocks
- Crypto in 2025: Regulations, Rollercoasters, and the Road Ahead
